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Abstract 
Background: This study was conducted to evaluate the effects of probiotic supplementation on metabolic profiles 
in diabetic patients with coronary heart disease (CHD).
Methods: This randomized, double‑blind, placebo‑controlled trial was performed among 60 diabetic patients with 
CHD, aged 40–85 years at a cardiology clinic in Kashan, Iran, from October 2017 through January 2018. Patients were 
randomly divided into two groups to take either probiotic supplements (n = 30) or placebo (n = 30) for 12 weeks. 
Fasting blood samples were taken at the beginning of the study and after the 12‑week intervention to determine 
related markers.
Results: After 12‑week intervention, probiotic supplementation significantly decreased fasting plasma glucose (β 
− 20.02 mg/dL; 95% CI − 33.86, − 6.17; P = 0.005), insulin (β − 2.09 µIU/mL; 95% CI − 3.77, − 0.41; P = 0.01), insulin 
resistance (β − 0.50; 95% CI − 0.96, − 0.03; P = 0.03) and total‑/HDL‑cholesterol ratio (β − 0.27; 95% CI − 0.52, − 0.03; 
P = 0.02), and significantly increased insulin sensitivity (β 0.008; 95% CI 0.001, 0.01; P = 0.02) and HDL‑cholesterol levels 
(β 2.52 mg/dL; 95% CI 0.04, 5.00; P = 0.04) compared with the placebo. Moreover, probiotic supplementation led to 
a significant reduction in serum high sensitivity C‑reactive protein (β − 0.88 mg/L; 95% CI − 1.39, − 0.38; P = 0.001), 
and a significant elevation in total antioxidant capacity (β 108.44 mmol/L; 95% CI 47.61, 169.27; P = 0.001) and total 
glutathione levels (β 45.15 µmol/L; 95% CI 5.82, 84.47; P = 0.02) compared with the placebo. Probiotic supplementa‑
tion did not affect other metabolic profiles.
Conclusions: Overall, we found that probiotic supplementation for 12 weeks had beneficial effects on glycemic con‑
trol, HDL‑cholesterol, total‑/HDL‑cholesterol ratio, biomarkers of inflammation and oxidative stress in diabetic patients 
with CHD.
Trial registration Clinical trial registration number http://www.irct.ir: IRCT2017082733941N5
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Background
Type 2 diabetes mellitus (T2DM) is considered as a 
developing epidemic that influences adult population 
[1]. Urbanization, changing dietary pattern and inactive 
lifestyle contribute to an elevating incidence of T2DM 
and coronary heart disease (CHD) [2]. Hyperglycemia 
and insulin resistance in patients with T2DM exert con-
siderable impacts on blood vessels, and demonstrated 
a capacity to increase the occurrence of retinopathy, 
nephropathy, and CHD [3]. Overall, patients with T2DM 
have higher risk of having cardiovascular disease (CVD) 
[4], which accounting for almost 60% of mortality related 
to diabetes [5].
The effects of probiotic supplementation, containing 
lactobacillus and bifidobacteria, on metabolic profiles 
have been reported frequently in previous studies in 
different populations, however to our best knowledge, 
probiotic supplementation have not been evaluated in 
diabetic patients with CHD. In addition, current evi-
dence is inconclusive. In a study, oral administration of 
2.5 × 109  CFU/g probiotic containing Bifidobacterium 
bifidum, Bifidobacterium lactis, Lactobacillus acido-
philus, Lactobacillus brevis, Lactobacillus casei, Lacto-
bacillus salivarius, Lactococcus lactis and Lactococcus 
lactis twice a day for 12  weeks to patients with T2DM 
decreased insulin resistance [6]. Furthermore, in a meta-
analysis conducted by Taylor et  al. [7]. 6–8  weeks pro-
biotic  supplementation decreased insulin resistance in 
women with gestational diabetes (GDM), while did not 
affect lipid profiles and fasting glucose. Earlier, we have 
documented that co-supplementation of 8 × 109  CFU/g 
probiotic, containing Lactobacillus acidophilus, Bifido-
bacterium bifidum, Lactobacillus reuteri, and Lactoba-
cillus fermentum (each 2 × 109) and 50,000  IU vitamin 
D every 2  weeks for 12  weeks to T2DM people with 
CHD  had beneficial effects on mental health param-
eters, inflammatory markers, total antioxidant capacity, 
glycemic control and HDL-cholesterol, although there 
was no effect on other parameters of metabolic profiles 
[8]. In another investigation, taking probiotic, contain-
ing 112.5 × 109 CFU/capsule of eight strains of lactic acid 
bacteria, for 8 weeks by women with GDM significantly 
modulated inflammatory markers, insulin and insulin 
resistance, although did not affect fasting glucose and 
HbA1c [9]. Discrepancies in these findings may be due to 
differences in study design, characteristics of study popu-
lations, dosage of probiotic and synbiotic used, type of 
bacteria used, and the duration of the intervention.
The beneficial effects of probiotic supplements on insu-
lin resistance, lipid profiles, biomarkers of inflamma-
tion and oxidative damage may be explained through its 
impacts on scavenging superoxide and hydroxyl radicals 
[10], decreased inflammatory signaling [11] and weight 
reduction [12]. According to existing evidence that pro-
biotic supplementation might have antioxidant and anti-
inflammatory properties and glucose-lowering effects; we 
assumed that probiotic consumption may benefit diabetic 
patients with CHD. Therefore, this study was conducted 
to determine the effects of probiotic supplementation on 
metabolic status in diabetic patients with CHD.
Methods
Study population
This study was a randomized, double-blind, placebo-con-
trolled trial registered in the Iranian registry of clinical 
trials (http://www.irct.ir: IRCT2017082733941N5) which 
performed at a cardiology clinic affiliated to Kashan Uni-
versity of Medical Sciences (KAUMS), Kashan, Iran, from 
October 2017 through January 2018. Inclusion criteria 
were as follows: patients with T2DM, aged 40–85  years 
old with 2- and 3-vessel CHD. T2DM was diagnosed 
based on the criteria of the American Diabetes Asso-
ciation [13]. Furthermore, the diagnosis of CHD was 
conducted following the American Heart Association 
guideline [14]. Exclusion criteria included consuming 
probiotic and/or synbiotic within 3 months prior to the 
intervention, taking prebiotic, antioxidant and/or anti-
inflammatory supplements such as vitamin E, vitamin 
C and omega-3 fatty acids, taking antibiotics, having an 
acute myocardial infarction, a cardiac surgery in the past 
3 months, renal or hepatic failure.
Ethical statement
The research was done following the Declaration of Hel-
sinki principals. The protocol of this study was approved 
by Research Ethics Committee, KAUMS, and Iran. Writ-
ten informed consent was taken from all participants.
Study design
Initially, we conducted a stratified randomization for all 
participants according to age, BMI, gender, the dosage 
and kind of medications, in order to decrease potential 
confounding effects. Then, participants in each stratum 
were randomly allocated into two treatment groups to 
take either probiotic supplements including Bifidobacte-
rium bifidum 2 × 109, Lactobacillus casei 2 × 109, Lacto-
bacillus acidophilus 2 × 109 CFU/day (n = 30) or placebo 
(n = 30) for 12 weeks. Color, shape, size, and package of 
placebos and probiotics capsules were identical and made 
by Tak Gen Zist Pharmaceutical Company (Tehran, Iran). 
Randomization was conducted using computer-gener-
ated random numbers. Randomization and allocation 
were concealed from the investigators and participants 
until the final analyses were completed. The randomized 
allocation sequence, enrolling participants and allocat-
ing them into intervention groups were performed by a 
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trained staff at cardiology clinic. At the beginning of the 
study, patients were requested to maintain their regular 
diet and levels of physical activity throughout the period 
of the trial. Compliance rate regarding the consump-
tion of placebos and probiotic supplements was deter-
mined by examining the returned capsule containers. 
All patients completed 3-day dietary records at baseline, 
week 1, 4, 8 and 12 of treatment. To determine nutrient 
intakes of participants according to 3-day food records, 
we used Nutritionist IV software (First Databank, San 
Bruno, CA). Physical activity was quantified as metabolic 
equivalents (METs) in hours per day [15]. Anthropomet-
ric measures (Seca, Hamburg, Germany) were measured 
at baseline and end of the intervention at the cardiology 
clinic by a trained staff. Nutritionist also was blinded to 
the randomization assignments.
Outcomes
Insulin metabolism was considered as primary outcome, 
however lipid profiles, biomarkers of inflammation and 
oxidative stress were considered as secondary outcomes. 
Fasting blood (10  mL) was taken at baseline and after 
the 12-week intervention at Kashan reference labora-
tory, Kashan, Iran. Insulin levels were measured using 
an ELISA kit (DiaMetra, Milano, Italy) with inter-assay 
and intra-assay coefficient variances (CVs) of lower than 
5%. The homeostasis model of assessment-insulin resist-
ance (HOMA-IR) and the quantitative insulin sensitivity 
check index (QUICKI) were calculated according to the 
standard formulas [16]. Enzymatic kits (Pars Azmun, 
Tehran, Iran) were used to determine fasting plasma glu-
cose (FPG) and lipid profiles with inter- and intra-assay 
CVs of lower than 5%. Hs-CRP levels were measured 
using an ELISA kit (LDN, Nordhorn, Germany) with 
inter- and intra-assay CVs of lower than 7%. Nitric oxide 
(NO) was measured by Griess assay [17], total antioxi-
dant capacity (TAC) the method reported by Benzie and 
Strain [18], total glutathione (GSH) by Beutler method 
[19], and MDA concentrations by the spectrophotomet-
ric test with inter- and intra-assay CVs of lower than 5% 
[20]. Systolic (SBP) and diastolic blood pressure (DBP) 
was measured using a sphygmomanometer (ALPK2, 
Zhejiang, China). Blood pressure values were reported in 
millimeters of mercury (mmHg).
Statistical methods and sample size
We calculated sample size using the formula suggested 
for randomized clinical. Type one (α) and type two errors 
(β) were defined as 0.05, and 0.20 (power = 80%), respec-
tively. According to the previous trial [21], we used 1.61 
as the SD and 2.30 as the mean change (d) of HOMA-IR. 
Based on the formula, 25 participants were required in 
each group; after allowing for 5 dropouts in each group, 
the final sample size was 30 participants per intervention 
group.
The Kolmogorov–Smirnov test was conducted to deter-
mine the normal distribution of variables. The analyses 
were repeated using intention-to-treat (ITT) protocol. 
Independent-samples t-test was used to detect the dif-
ferences in anthropometric measures and dietary intakes 
between two groups. Multiple linear regression mod-
els were applied to evaluate treatment impacts on study 
outcomes after adjusting for confounding parameters 
including; age, and BMI. The effect sizes were presented 
as the mean differences with 95% confidence intervals. 
Bootstrapping was also used as a sensitivity analysis of 
confidence intervals. Pearson Chi square test was applied 
for the comparison of categorical variables. P values 
< 0.05 were considered significant. The Statistical Package 
for Social Science version 18 (SPSS Inc., Chicago, Illinois, 
USA) was used for statistical analyses of this trial.
Results
Sixty patients [probiotic (n = 30) and placebo (n = 30)] 
completed the trial (Fig.  1). In our study, the compli-
ance rate was high, such that more than 90% of capsules 
were consumed throughout the study in both groups. No 
adverse effects were recorded in diabetic patients with 
CHD following probiotic supplementation.
There were no significant differences between two 
groups in terms of mean age, height, baseline weight, 
BMI, and mean changes in weight and BMI throughout 
the trial (Table  1). In addition, smoking status, taking 
antidiabetic and antilipidemic agents, incidence of hyper-
tension, consumption of angiotensin converting enzymes 
inhibitors (ACEI), aldosterone receptor blockers (ARB) 
drugs and blocker drugs (β-blocker and calcium chan-
nel blocker) were not statistically different between two 
intervention groups.
Based on 3-day dietary records, obtained at baseline 
and throughout the intervention, we observed no sig-
nificant difference in macro- and micronutrients intake 
between the two groups (Table 2).
Probiotic supplementation significantly decreased FPG 
(β − 20.02  mg/dL; 95% CI − 33.86, − 6.17; P = 0.005), 
serum insulin levels (β − 2.09  µIU/mL; 95% CI − 3.77, 
− 0.41; P = 0.01), HOMA-IR (β − 0.50; 95% CI − 0.96, 
− 0.03; P = 0.03) and total-/HDL-cholesterol ratio (β 
− 0.27; 95% CI − 0.52, − 0.03; P = 0.02), and significantly 
increased QUICKI (β 0.008; 95% CI 0.001, 0.01; P = 0.02) 
and HDL-cholesterol levels (β 2.52 mg/dL; 95% CI 0.04, 
5.00; P = 0.04) compared with the placebo (Table  3). 
In addition, probiotic supplementation led to a signifi-
cant reduction in serum hs-CRP (β − 0.88  mg/L; 95% 
CI − 1.39, − 0.38; P = 0.001), and a significant increase 
in plasma TAC (β 108.44 mmol/L; 95% CI 47.61, 169.27; 
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P = 0.001) and GSH levels (β 45.15 µmol/L; 95% CI 5.82, 
84.47; P = 0.02) compared with the placebo. Probiotic 
supplementation did not affect other metabolic profiles. 
When we adjusted the analysis for smoking status and 
familial history of CHD, findings remained intact.
Discussion
This study demonstrated that taking probiotics for 
12  weeks by diabetic patients with CHD had beneficial 
effects on glycemic control, improving HDL levels- and 
total-/HDL-cholesterol ratio, and attenuating biomark-
ers of inflammation and oxidative stress. The observed 
difference in glycemic control, HDL-, total-/HDL-choles-
terol ratio, inflammatory markers and oxidative stress in 
our study was statistically significant between two inter-
vention groups, however, it was not clinically significant. 
Long-term interventions and higher dosages of probiotic 
supplements might result in greater changes in these 
metabolic profiles.
Effects on glycemic control and lipid profiles
A few studies have evaluated the effects of probiotic 
supplementation on glycemic control and lipid profiles 
among diabetic patients; however this data is scarce 
among diabetic patients with CHD. In a meta-analysis 
conducted by Yao et  al. [22], probiotic ingestion signifi-
cantly reduced HbA1c and insulin levels in patients with 
T2DM, but did not affect their lipid profiles. In addition, 
Taylor et al. [7]. found that probiotic supplementation for 
6–8  weeks resulted in a significant reduction in insulin 
resistance in pregnant women with GDM, but did not 
influence their lipid profiles and fasting glucose levels. 
Furthermore, it was reported that gut microbiota con-
tributes to glucose homeostasis through different bacte-
rial metabolites [23]. Previous meta-analyses revealed 
that probiotic supplementation decreased insulin resist-
ance and glycated hemoglobin levels [24, 25]. In contrast, 
such beneficial effects were not reported by others [26–
29]. Insulin resistance and dyslipidemia in patients with 
T2DM increase the risk of microvascular complications 
and cardiovascular mortality [30]. Therefore, probiotic 
administration might be useful to decrease diabetic com-
plications, due to its glucose-lowering effect. Improved 
glucose homeostasis parameters, HDL- and total-/HDL-
cholesterol ratio by probiotics among diabetic patients 
with CHD may be related to their role in decreasing 
inflammatory cytokines and suppressing the nuclear 
factor-κB pathway [31], their impact on gene expression 
[12] and the activation of gut microbiota-short chain 
fatty acids (SCFA)-hormone axis [32].
Randomized (n=60)
Allocated to placebo (n=30)
Lost to follow-up (n=0)
Analyzed (n=30)
Allocated to intervention (n=30)
Lost to follow-up (n=0)
Analyzed (n=30)
Assessed for eligibility (n=65)
Excluded (n=5) 






















Fig. 1 Summary of patient flow diagram
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Effects on biomarkers of inflammation and oxidative stress
We have previously shown that taking probiotics 
by  patients with major depressive disorder for 8  weeks 
improved hs-CRP and GSH concentrations, but did not 
influence TAC levels [28]. Furthermore, a significant 
reduction in hs-CRP levels was seen after taking pro-
biotic supplements for 48  weeks by HIV-infected indi-
viduals [33]. On the other hand, no significant changes 
in MDA and TAC levels were found following probiotic 
capsule supplementation containing Lactobacillus casei 
 (108  CFU/g) for 8  weeks in patients with rheumatoid 
arthritis [34]. Diabetes is correlated with enhanced con-
centrations of vascular inflammation and oxidative stress 
parameters [35]. Cell culture studies suggest that elevated 
pro-inflammatory markers may cause a reduction in GSH 
synthesis [36, 37]. Discrepancies in these findings may be 
explained through the differences in study design, char-
acteristics of study populations, probiotic species, strains 
and formulations available, and duration of the interven-
tion. Probiotics ingestion may decrease inflammation and 
oxidative stress through increased production of SCFA in 
the colon, improved activity of glutamate-cysteine-ligase 
activity (GCL) and increased gene expression of GCL 
subunits [38].
This study had few limitations. In the current study, 
fecal bacterial loads were not measured before and after 
probiotic consumption. Also, there was no chance to 
evaluate gene expression of lipid, insulin, inflammation 
and oxidative damage in diabetic patients with CHD.
Conclusions
Overall, probiotic supplementation for 12  weeks had 
beneficial effects on glycemic control, HDL-cholesterol, 
total-/HDL-cholesterol ratio, biomarkers of inflam-
mation and oxidative stress in diabetic patients with 
CHD. Our findings clarify that probiotic supplemen-
tation may confer advantageous therapeutic impacts 
Table 1 General characteristics of  study participants 
at baseline study
Data are means ± SDs
ACEI Angiontensin converting enzymes inhibitors, ARB Aldosterone receptor 
blockers, CHD coronary heart disease, DM diabetes mellitus
1 Obtained from independent t-test






Age (year) 61.8 ± 9.8 60.7 ± 9.4 0.64
Familial history (%) 10 (33.7) 11 (36.7) 0.78†
Height (cm) 163.2 ± 7.1 162.5 ± 7.2 0.72
Weight at study baseline 
(kg)
78.2 ± 11.8 80.2 ± 15.3 0.57
Weight at end‑of‑trial 
(kg)
78.2 ± 12.0 80.2 ± 15.3 0.56
Weight change (kg) − 0.03 ± 1.1 0.04 ± 1.0 0.78
BMI at study baseline 
(kg/m2)
29.3 ± 4.1 30.3 ± 5.2 0.42
BMI at end‑of‑trial (kg/
m2)
29.3 ± 4.1 30.3 ± 5.2 0.41
BMI change (kg/m2) − 0.01 ± 0.4 0.06 ± 0.4 0.81
Smoking (%) 3 (10.0) 3 (10.0) 1.00†
Aspirin 80 mg (%) 30 (100) 30 (100) 1.00†
Statin (%) 30 (100) 30 (100) 1.00†
Insulin therapy (%) 8 (26.7) 7 (23.3) 0.76†
Antidiabetic drugs (%)
 Monotherpy 16 (72.7) 17 (70.8)
 Combination therapy 6 (27.3) 7 (29.2) 0.88†
Hypertension (%) 22 (73.3) 23 (76.7) 0.76†
ACEI/ARB drugs (%) 30 (100) 30 (100) 1.00†
Blocker drugs (%)
 β‑blocker 28 (93.3) 29 (96.7)
 Calcium channel 
blocker
2 (6.7) 1 (3.3) 0.55†
Duration of DM (year) 6.8 ± 2.2 6.6 ± 1.9 0.61
Duration of CHD (year) 9.5 ± 2.2 9.3 ± 1.6 0.78
Table 2 Mean dietary intakes of  study participants 
at study baseline and throughout the study
Values are means ± SDs
MUFAs monounsaturated fatty acids, PUFAs polyunsaturated fatty acids, SFAs 
saturated fatty acids TDF total dietary fiber






Energy (kcal/day) 2182 ± 215 2194 ± 224 0.83
Carbohydrates (g/day) 292.1 ± 38.1 298.5 ± 43.5 0.54
Protein (g/day) 82.5 ± 23.5 81.5 ± 17.8 0.85
Fat (g/day) 79.8 ± 14.6 79.0 ± 13.1 0.80
SFA (g/day) 26.1 ± 5.9 25.9 ± 5.5 0.92
MUFA (g/day) 22.7 ± 6.3 22.1 ± 5.7 0.69
PUFA (g/day) 23.4 ± 4.3 22.7 ± 4.3 0.50
Cholesterol (mg/day) 219.5 ± 128.9 205.1 ± 100.6 0.63
TDF (g/day) 19.1 ± 3.8 19.5 ± 4.1 0.69
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for diabetic patients with CHD. Further research is 
required in other populations and for longer period 
of time to determine the beneficial effects of probiotic 
supplementation.
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Table 3 The effect of  probiotic supplementation on  metabolic status in  type 2 diabetic patients with  coronary heart 
disease
Data are mean ± SDs
DBP diastolic blood pressure, FPG fasting plasma glucose, GSH total glutathione, HOMA-IR homeostasis model of assessment-estimated insulin resistance, hs-CRP 
high-sensitivity C-reactive protein, MDA malondialdehyde, NO nitric oxide, QUICKI quantitative insulin sensitivity check index, SBP systolic blood pressure, TAC total 
antioxidant capacity
a ”Outcome measures” refers to the change in values of measures of interest between baseline and week 12. β [difference in the mean outcomes measures between 
treatment groups (probiotic group = 1 and placebo group = 0)]
2 Obtained from multiple regression model (adjusted for baseline values of each biochemical variables, age and baseline BMI)
Variables Placebo group (n = 30) Probiotic group (n = 30) Difference in outcome measures 
between probiotic and placebo 
treatment  groupsa
Baseline Week 12 Baseline Week 12 β (95% CI) P2
FPG (mg/dL) 128.8 ± 47.2 138.2 ± 33.5 133.8 ± 43.6 120.6 ± 38.7 − 20.02 (− 33.86, 6.17) 0.005
Insulin (μIU/mL) 13.8 ± 8.6 14.7 ± 8.5 14.3 ± 5.6 13.1 ± 5.2 − 2.09 (− 3.77, − 0.41) 0.01
HOMA‑IR 4.5 ± 3.6 4.6 ± 3.2 4.8 ± 2.7 4.4 ± 2.4 − 0.50 (− 0.96, − 0.03) 0.03
QUICKI 0.32 ± 0.03 0.31 ± 0.02 0.31 ± 0.02 0.31 ± 0.02 0.008 (0.001, 0.01) 0.02
Triglycerides (mg/dL) 146.2 ± 67.4 152.4 ± 66.9 139.0 ± 61.3 140.2 ± 64.9 − 8.93 (− 30.54, 12.68) 0.41
VLDL‑cholesterol (mg/dL) 29.2 ± 13.5 30.5 ± 13.4 27.8 ± 12.3 28.1 ± 13.0 − 1.78 (− 6.10, 2.53) 0.41
Total cholesterol (mg/dL) 143.5 ± 30.5 146.3 ± 34.0 149.7 ± 26.6 144.6 ± 27.2 − 6.62 (− 18.86, 5.62) 0.28
LDL‑cholesterol (mg/dL) 71.2 ± 26.3 73.0 ± 24.1 74.9 ± 22.0 68.1 ± 21.1 − 6.68 (− 15.53, 2.15) 0.13
HDL‑cholesterol (mg/dL) 43.0 ± 7.2 42.8 ± 6.2 46.8 ± 6.7 48.4 ± 7.4 2.52 (0.04, 5.00) 0.04
Total‑/HDL‑cholesterol ratio 3.4 ± 0.8 3.4 ± 0.7 3.2 ± 0.6 3.0 ± 0.6 − 0.27 (− 0.52, − 0.03) 0.02
hs‑CRP (mg/L) 4.8 ± 2.5 4.9 ± 2.6 5.1 ± 2.8 4.3 ± 2.6 − 0.88 (− 1.39, − 0.38) 0.001
NO (µmol/L) 46.6 ± 10.0 44.2 ± 8.3 42.4 ± 6.2 46.5 ± 7.4 4.28 (0.66, 7.91) 0.02
TAC (mmol/L) 895.3 ± 301.9 873.3 ± 276.3 965.5 ± 239.4 1044.4 ± 254.9 108.44 (47.61, 169.27) 0.001
GSH (µmol/L) 506.3 ± 96.5 505.3 ± 107.9 586.2 ± 156.3 629.4 ± 169.5 45.15 (5.82, 84.47) 0.02
MDA (µmol/L) 2.7 ± 0.7 2.6 ± 0.4 3.1 ± 1.3 2.7 ± 1.4 − 0.23 (− 0.53, − 0.07) 0.13
SBP (mmHg) 128.3 ± 14.4 127.0 ± 15.1 125.1 ± 12.8 123.2 ± 13.3 − 1.30 (− 5.96, 3.35) 0.57
DBP (mmHg) 79.3 ± 8.8 78.2 ± 8.5 77.9 ± 6.9 76.2 ± 8.0 − 1.08 (− 3.51, 1.35) 0.37
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